1.Purification of a Recombinant Human GST/MCP-1 Fusion Protein and Its Antitumor Effection
Yi ZHANG ; Jiabo TENG ; Qinong YE
Chinese Journal of Cancer Biotherapy 1995;0(03):-
GST/MCP-1 fusion protein was overexpressed in Escherichia coli as inculstion bodies. After isolation of the inclusion bodies, the optimum conditions of denaturation and renaturation were studied. The renatured produts were purified to be electroporetically pure by affinity chromatography on immobilised glutathione. The purified product remains biological activities and can react specifically with MCP-1 antibodies by western blot analysis. The in vitro antitumor effect showed that GST/MCP-1 could activate monocytes and lymphocytes to inhibit the growth of a lung adenocarcinoma cell line A549. In vivo, GST/MCP-1 could inhibit the tumor growth in nude mice. These results suggested that MCP-1 had antitumor effect.
2.Embedded information service for research on aviation medicine
Li YU ; Yan JIAO ; Jiabo YE ; Qing HE ; Fanhu ZHONG
Chinese Journal of Medical Library and Information Science 2015;24(12):35-37
Described in this paper are the contents and objectives of embedded information service for research on aviation medicine in light of information access, identification and analysis in persons engaged in research on aviation medicine.
3.Effects of different dosages of BMSC on lung fibrosis in mice
Jiabo XU ; Yanqin LI ; Li LI ; Bin LIU ; Jianfei XIONG ; Qing YE
Journal of Shanghai Jiaotong University(Medical Science) 2009;29(10):1157-1162
Objective To investigate the effects of different dosages of bone marrow mesenchymal stromal cells (BMSC) on lung fibrosis. Methods BMSCs with red fluorescence protein (RFP) from male FVB mice were cultured in vitro. Twenty-four female wild type FVB mice were randomly divided into four groups: normal group, model group, BMSC 1 group and BMSC 2 group (n = 6). Mouse pulmonary fibrosis models were induced by bleomycin via single intratracheal perfusion. Twenty-four h after model establishment, mice in BMSC 1 group and BMSC 2 group were injected with 1 × 10~6 BMSCs and 2 × 10~6 BMSCs, respectively through vena caudalis for each mouse. All the animals were sacrificed 21 d after model estalishment, and mouse lung tissue samples were obtained. The pathological changes were observed by light microscopy, the hydroxyproline ( Hyp) contents were measured by alkaline hydrolysis assay, the distribution of RFP( + ) BMSCs and quantitation of RFP were analysed by laser scanning confocal microscopy and immunohistochemistry, the expression of surfactant protein A (SP-A) was detected by immunohistochemistry, and the expression of transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF) mRNA was detected by Real-time PCR. Results Compared with model group, the pulmonary fibrosis in BMSC 1 group was significantly alleviated, and that of BMSC 2 group became much more severe.A large number of RFP( +) BMSCs were found in fibrosis area of BMSC 2 group,which exhibited morphology similar to fibroblasts. As far as the expression of SP-A was concerned, normal group was higher than BMSC 1 group, BMSC 1 group was higher than BMSC 2 group and model group (P < 0. 05), while there was no significant difference between BMSC 2 group and model group (P >0. 05). Normal group, BMSC I group, model group and BMSC 2 group fell in the increase order by Hyp contents (P <0.01, P <0.05), and BMSC 2 group, BMSC 1 group, model group and normal group fell in the decrease order by expression of TCF-|$ and PDGF mRNA (P < 0.05). Conclusion Proper dose of BMSC has a favourable effect on bleomycin-induced lung fibrosis, while excessive dose of BMSC can aggravate the fibrosis.
4.Construction of military aviation audiovisual information system based on media assets management
Jiabo YE ; Xia ZHANG ; Zhixiang WANG ; Li YU ; Qing HE ; Yanyan CHEN
Chinese Journal of Medical Library and Information Science 2015;(11):78-80
A military aviation audiovisual information system was constructed using the recent media assets manage-ment technologies according to the audiovisual data in our institute since its establishment,which will realize the scien-tific,standard,digital and network management of audiovisual information,and further improve the audiovisual service.
5.Related risk factors of central lymph node metastasis in papillary thyroid microcarcinoma of cN0 stage
Jinqiu WANG ; Li ZHANG ; Jiabo ZHANG ; Xianneng SHENG ; Dan YE ; Yu GUO
Chinese Journal of Endocrine Surgery 2020;14(4):279-283
Objective:To investigate the risk factors of lymph node metastasis in the cervical region VI (central region) in patients with papillary thyroid microcarcinoma (PTMC) of cN0 stage, and then to determine whether to perform prophylactic central lymph node dissection.Methods:The clinical data of 500 patients with PTMC who underwent surgery from Jan. 2013 to Dec. 2015 in Ningbo First Hospital were retrospectively analyzed. Due to the pathological results, all patients were divided into two groups: central lymph node metastasis (CLNM) positive group and CLNM negative group. SPSS18.0 was used for analyzing.Results:Of the 500 cases of PTMC of cN0 stage, 142 cases had lymph node metastasis. Gender, the maximum tumor diameter, tumor invasion outside the gland, boundary, calcification in tumor, single or multiple lesions, aspect ratio and blood flow were risk factors for CLNM in patients with PTMC of cN0 stage. Multivariate analysis identified that male ( P=0.014) , tumor size ≥0.5 cm ( P=0.03) , tumor invasion outside the gland ( P=0.003) , unclear boundary ( P=0.032) , calcification ( P=0.009) , aspect ratio ≥1 ( P=0.001) were independent predictors factors for CLNM of PTMC. Conclusion:Male, unclear boundary, tumor size ≥0.5cm, tumor invasion outside the gland, calcification, aspect ratio ≥1 are the risk factors of CLNM in patients with cN0 PTMC. Prophylactic central lymph node dissection should be performed for patients without lymph node metastasis but with one risk factor or more.
6.Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injuryIssued by China Food and Drug Administration.
Xiaohe XIAO ; Jianyuan TANG ; Yimin MAO ; Xiuhui LI ; Jiabo WANG ; Chenghai LIU ; Kewei SUN ; Yong'an YE ; Zhengsheng ZOU ; Cheng PENG ; Ling YANG ; Yuming GUO ; Zhaofang BAI ; Tingting HE ; Jing JING ; Fengyi LI ; Na AN
Acta Pharmaceutica Sinica B 2019;9(3):648-658